Keywords: Activartis, Cancer vaccine, Brain cancer, Ph II

Activartis develops dendritic cell-based cancer vaccine in Ph II; will seek partner

Article | 27 October 2011

Privately-held Austrian company Activartis GmbH (formerly Trimed Biotech) is developing a cancer immunotherapy concept which is currently in Phase II ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Activartis

Go to company listing